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ABSTRACT 
Hepatitis means inflammation of the liver, with accompanying damage to liver cells. Hepatitis is classified into chronic and acute hepatitis and the 
different types are hepatitis A, B, C, D and E. However, their causes, modes of transmission, incubation periods, signs and symptoms, diagnosis, 
treatments and preventions were also discussed. Hepatitis causes liver diseases such as liver cirrhosis, hepatocellular carcinoma, and jaundice. It is 
reviewed that when chronic hepatitis C or B goes untreated, it causes scarring to the liver (cirrhosis) and an increased chance of liver cancer and 
liver failure, ending in death. Hepatitis viruses, especially Hepatitis A Virus (HAV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection are 
endemic in Nigeria and constitute a public health menace, the prevalence of HBV in some professional group was found to be highest among the 
female sex workers (FSWs). Global prevalence of chronic HAV and HBV infection is highest in Africa, Asia and Western Pacific; intermediate in 
Southern and Eastern Europe and Lowest in Western Europe, North America and Australia. Pregnant women, in the 3rd trimester of gestation are 
found to be more likely to be infected than those in the 1st and 2nd trimester, thus, the virus can be transmitted from the infected mother to the 
offspring during birth. The group of people who stood the high risk of contracting both HAV and HBV infections were also revealed. It is 
recommended that hepatitis screening should be incorporated in the routine antenatal check up, and government at all levels should be proactive in 
innovation and immediate implementation of a general child and adolescent immunization against HBV to prevent further spread of this virus.  
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INTRODUCTION 
Despite the availability of a safe and effective vaccine against 
hepatitis infection for over two decades now, the overall burden of 
the disease remains enormous with over two billion people infected 
worldwide and approximately one million deaths occur annually 
from hepatitis related diseases (Lavanchy, 2004). Several studies 
have demonstrated that hepatitis especially hepatitis B virus (HBV) 
is endemic in Nigeria and have the seroprevalence among various 
groups (Olubuyide et al., 1997; Belo, 2000; Odemuyiwa et al., 2001; 
Cobelens et al., 2004). Most of the information of HBV prevalence in 
Nigeria is available from blood donors (Otegbayo et al., 2003; Ejele 
and Ojule, 2004). It is highly prevalent among the female sex 
workers (FSW) and pregnant women in Nigeria. Hepatitis is one of 
the diseases in pregnancy that causes jaundice in women, and if left 
untreated may lead to the birth of babies with low intelligent 
quotient (IQ). 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major public 
health concern (Wasley and Alter, 2000; Modi and feld, 2007). Like 
in the case of HIV, the highest incidence of the acute hepatitis is 
among the young adults. Therefore, as a result of all these burdens 
the disease cause to human, I deem it right to undertake this study to 
discuss on the hepatitis and the physiology of liver cells. 
General Overview of Hepatitis 
The word hepatitis was coined from two Greek words hepat- liver 
and itis–inflammation. Thus, hepatitis means inflammation of the 
liver, with accompanying damage to liver cells (BMA, 2008). 
Hepatitis is a general term meaning inflammation of the liver and 
can be caused by a variety of different viruses such as hepatitis A, B, 
C, D and E. Hepatitis B virus (HBV) infection is endemic in Nigeria 
and constitutes a public health menace (Ndams et al., 2008). WHO 
(1990), reported that Nigeria is a highly endemic area with a 
prevalence greater than 8 %. The prevalence of HBV in normal 
population in Nigeria ranges from 2.7 % to 13.3 % (Kulkarinii et al., 
1986; Muula, 2000). HBV spot surveys amongst pregnant women in 
the country revealed a prevalence of 4.3 % in Port Harcourt (Akani 
et al., 2005), 15.1 % in Jos (Egah et al., 2007), 8.3 % in Zaria (Luka et 
al., 2008), 11.6 % in Maiduguri (Harry et al., 1994), 13.8 % in Lagos 
(Nasidi et al., 1993), 5.7 % in Ilorin (Agbede et al., 2007) and 2.19 % 
in Benin City (Onakewhor et al., 2008). Prevalent rate in other cities 
in Nigeria are yet to be investigated.  
Similar studies in other parts of the world reported a prevalence of 
10% in Hong Kong (Kong et al., 1997), 10% in India (Sharma et al., 
1995), 12 % in Taiwan (Lin et al., 2003), 17.3 % in Burkino Faso 
(Collenberg et al., 2006), 11 % in Papua New Guinea (Clegg, 1991) 
and 3.7 % in Ethiopia (Awole and Gebre-Slassie, 2005). According to 
Juszozyk (2000), the global prevalence of chronic hepatitis B virus 
(HBV) infection varies, being highest in Africa, Asia and Western 
Pacific (>8 %), intermediate (2-7 %) in southern and Eastern Europe 
and lowest (<2 %) in Western Europe, North America and Australia. 
A hepatitis B positive mother also confers the risk of passing the 
infection to her offspring. Siriprakash and Anil (1997), reported that 
neonates who contact HBV infection will almost have 90 % risk of 
developing chronic hepatitis and chronic liver disease. Otegbayo et 
al. (2008) reported that there is overlap in risk factor for HIV, HBV 
and HCV. HIV co-infection with HBV and /or HCV is associated with 
increased risks of Liver- related morbidity and mortality among the 
HIV/AIDS patients (Garcia et al., 2001; Thio et al., 2002).  
According to WHO (2003), the global burden of HCV and HBV is 170 
million and 400 million respectively. As at 2010, China has 120 
million infected people, followed by India and Indonesia with 40 
million and 12 million respectively. So far, in March 2002, 151 
countries have introduced hepatitis B vaccine within their national 
immunization programmes (Kane, 1998; VHPB, 1996; VHPB, 1998). 
In other countries, universal vaccination is still being postponed. The 
reasons for this are the weakness of a social commitment to 
preventive medicine and vaccines, the lack of medical and public 
awareness, the view of hepatitis B infection as a limited public health 
problem that does not justify the expense and other efforts of 
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universal immunization, and the financial burden of national 
programmes (Iwarson, 1998; VHPB, 1996; VHPB, 1998). 
Liver Cells 
 
Fig. 1: A, Normal gross anatomy of a liver, B, histological slide, 
B’, histological view. 
A hepatocyte is a cell of the main tissue of the liver. Hepatocytes 
make up 70-80% of the liver's cytoplasmic mass. These cells are 
involved in, Protein synthesis, Protein storage, Transformation of 
carbohydrates, Synthesis of cholesterol, bile salts and phospholipids 
and detoxification, modification, and excretion of exogenous and 
endogenous substances. The hepatocyte also initiates formation and 
secretion of bile. Liver is the largest organ in the body, contributing 
about 2 % of the total body weight, or about 1.5 kg in the average 
adult human (Guyton and hall, 2006). It is a roughly wedge-shaped, 
red-brown structure lies in the upper abdominal cavity, directly 
below the diaphragm (BMA, 2002). The liver is divided into two 
main lobes (right and left lobe), both containing 50,000 to 100,000 
individual lobules in human (BMA, 2002). The lobules are 
surrounded by branches of the hepatic artery, which supplies the 
liver with oxygenated blood, and the portal vein, which supplies 
nutrient-rich blood (BMA, 2002). Some biochemical parameters are 
contained in the liver which helps in the normal processes of the 
liver cells. Some of these parameters include Aspartate 
aminotransferase (AST), Alanine aminotransferase (ALT), total and 
direct serum bilirubin, total protein, alkaline phosphatase (ALP), 
prothrombin time, albumin etc. Under normal liver conditions, the 
laboratory results shows elevated levels of some of the parameters 
stated above. The normal values of AST in adult male and female is 
14 – 20 U/L and 10-36 U/L respectively, ALT levels are 10-40 U/L 
and 7-35 U/L in male and females respectively (Chernecky and 
Berger, 2008). Total bilirubin in normal adult is 0.3-1.0 mg/dl, Urea 
is 2.5-7.5 mmol/L. 
Moreover, under abnormal conditions, may be when someone gets 
hepatitis, the liver will no longer perform the above functions as 
supposed to be and can be affected to varying degrees (Guyton and 
Hall, 2006). When this happens, some of the biochemical parameters 
in the liver (liver panels) such as bilirubin, ALT, AST, albumin, total 
proteins e.t.c, will vary either above or below normal levels 
(Robinson, 1995; Hollinger and Liang, 2001). The varying levels of 
the liver panels indicate that liver has been impaired; this may result 
to liver cirrhosis, liver cancer, jaundice etc. 
Functions of Hepatocyte 
Liver plays a vital role in the body because it produces and processes 
a wide range of chemical substances (BMA, 2002). The substances 
include important proteins for blood plasma, such as albumin. The 
liver also produces cholesterol and special proteins that help the 
blood to carry fats around the body. In addition, liver cell secrete 
bile, which removes waste products from the liver and aids the 
breakdown and absorption of fats in the small intestine. Another 
major function is the processing of nutrients for use by cells. The 
liver also stores excess glucose as glycogen. Similarly, it controls the 
blood level of amino acids. If the level of amino acids is too high, the 
liver converts the excess into glucose, proteins, other amino acids, or 
urea (for excretion). Finally, the liver helps to clear the blood of 
drugs and poisons by breaking them down and excreted in the bile 
or urine (detoxification). 
Histology of the Hepatocyte 
Hepatocytes display an eosinophilic cytoplasm, reflecting numerous 
mitochondria, and basophilic stippling due to large amounts of 
rough endoplasmic reticulum and free ribosomes. Brown lipofuscin 
granules are also observed (with increasing age) together with 
irregular unstained areas of cytoplasm; these correspond to 
cytoplasmic glycogen and lipid stores removed during histological 
preparation. The average life span of the hepatocyte is 5 months; 
they are able to regenerate. Hepatocyte nuclei are round with 
dispersed chromatin and prominent nucleoli. Anisokaryosis is 
common and often reflects tetraploidy and other degrees of 
polyploidy, a normal feature of 30-40% of hepatocytes in adult 
human liver (Séverine Celton-Morizur et al., 2010). Binucleate cells 
are also common. Hepatocytes are organised into plates separated 
by vascular channels (sinusoids), an arrangement supported by a 
reticulin (collagen type III) network. The hepatocyte plates are one 
cell thick in mammals and two cells thick in the chicken. Sinusoids 
display a discontinuous, fenestrated endothelial cell lining. The 
endothelial cells have no basement membrane and are separated 
from the hepatocytes by the space of Disse, which drains lymph into 
the portal tract lymphatics. Kupffer cells are scattered between 
endothelial cells; they are part of the reticuloendothelial system and 
phagocytose spent erythrocytes. Stellate (Ito) cells store vitamin A 
and produce extracellular matrix and collagen; they are also 
distributed amongst endothelial cells but are difficult to visualise by 
light microscopy. 
Hepatocytes are an important physiological example for evalutation 
of both biological and metabolic effects of xenobiotics. They are 
separated from the liver by collagenase digestion, which is a two 
step process. In the first step, the liver is placed in an isotonic 
solution, in which calcium is removed to disrupt cell-cell tight 
junctions by the use of a calcium chelating agent. Next, a solution 
containing collagenase is added to separate the hepatocytes from the 
liver stroma. This process creates a suspension of hepatocytes, 
which can be cultured and plated on 96 well plates for immediate 
use, or cryopreserved by freezing (Li and Albert, 2011). They do not 
proliferate in culture. Hepatocytes are intensely sensitive to damage 
during the cycles of cryopreservation including freezing and 
thawing. Even after the addition of classical cryoprotectants, there is 
still damage done while being cryopreserved (Hamel, 2006).  
Classes of Hepatitis 
Hepatitis is grouped into two major classes, they are as follows: 
 Acute hepatitis 
 Chronic Hepatitis 
Acute Hepatitis 
Acute hepatitis is short-term inflammation of the liver. In some 
cases, acute hepatitis may progress to chronic hepatitis if left 
untreated, but it rarely leads to acute liver failure (BMA, 2002). 
Acute hepatitis is fairly common. The most frequent cause is 
infection with a hepatitis virus, but can be caused by other infections 
such as cytomegalovirus infection. It may also result from an 
overdose of halothane or paracetamol or exposure to toxic chemicals 
including alcohol. Symptoms range from mild to severe pain, fever 
and jaundice. 
Chronic Hepatitis 
This is a long term inflammation of the liver. It eventually causes 
scar tissues to form and leads to liver cirrhosis. Chronic hepatitis 
may develop following an attack of acute hepatitis. It is a leading 
cause of liver related deaths among patients with HIV/AIDS 
worldwide (Koziel and Peters, 2007). It may also occur as a result of 
autoimmune disorder or, more rarely due to a metabolic disorder, 
such as haemochromatosis or wilson’s disease. Chronic hepatitis 
may cause slight tiredness or no symptoms at all. 
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Types of Hepatitis 
Five types of hepatitis exist, but the first three are the most common. 
They are Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D and 
Hepatitis E 
Hepatitis A 
Hepatitis A, one of the oldest diseases known to humankind, is a self-
limited disease which results in fulminant hepatitis and death in 
only a small proportion of patients. It is also called epidemic 
hepatitis. Hepatitis A was formerly called Infectious hepatitis, 
Epidemic hepatitis, Epidemic jaundice, Catarrhal jaundice and Type 
A hepatitis, HA  and caused by hepatitis A virus (HAV) (Stapleton 
and lemon, 1994 and Hollinger and Ticehurst, 1996). Hepatitis A is 
actually considered less destructive than some other hepatitis 
viruses. Unlike some other hepatitis viruses, hepatitis A virus rarely 
leads to a permanent liver damage. Also, HAV affects all age groups 
and, once someone has recovered from the infection, that person has 
immunity to the virus, and he or she may probably never get it again. 
However, it is a significant cause of morbidity and socio-economic 
losses in many parts of the world (Stapleton and lemon, 1994 and 
Hollinger and Ticehurst, 1996). Transmission of HAV is typically by 
the faecal-oral route (lemon, 1994; Stapleton, 1995; Hollinger and 
Ticehurst, 1996; Stapleton and Lemon, 1997). Infections occur early 
in life in areas where sanitation is poor and living conditions are 
crowded. With improved sanitation and hygiene, infections are 
delayed and consequently the number of persons susceptible to the 
disease increases. Under these conditions, explosive epidemics can 
arise from faecal contamination of a single source.  
HAV is resistant to thermal denaturation (survives at 70°C for up to 
10 min), acid treatment (pH 1 for 2 h at room temperature), 20% 
ether, chloroform, dichlorodifluoromethane, and 
trichlorotrifluoroethane, perchloracetic acid (300 mg/l for 15 min at 
20°C), detergent inactivation (survives at 37°C for 30 min in 1% 
SDS) and storage at -20°C for years. Also, the virus (HAV) can be 
inactivated by heating to 85°C for 1min, autoclaving (121°C for 20 
min), ultraviolet radiation (1.1 W at a depth of 0.9 cm for 1 min), 
formalin (8% for 1 min at 25°C), ß-propriolactone (0.03% for 72 h at 
4°C), potassium permanganate (30 mg/l for 5 min), iodine (3 mg/l 
for 5 min), chlorine (free residual chlorine concentration of 2.0 to 
2.5 mg/l for 15 min), chlorine-containing compounds (3 to 10 mg/l 
sodium hypochlorite at 20°C for 5 to 15 min) and shellfish from 
contaminated areas should be heated to 90°C for 4 min or steamed 
for 90 sec before use. 
Endemicity of Hepatitis A 
Geographical areas can be characterized by high, intermediate, or 
low levels of endemicity patterns of HAV infection. The levels of 
endemicity correlate with hygienic and sanitary conditions of each 
geographical area (Melinick, 1995; Steffen, 1995; Hollinger and 
Ticehurst, 1996; VHPB, 1997; Koff, 1998). In developing countries 
with very poor sanitary and hygienic conditions (parts of Africa, Asia 
and Central and South America), infection is usually acquired during 
early childhood as an asymptomatic or mild infection. Reported 
disease rates in these areas are therefore low and outbreaks of 
disease are rare. Reported disease incidence may reach 150 per 
100,000 per year.  
Similarly, developing countries with transitional economies and 
some regions of industrialized countries where sanitary conditions 
are variable (Southern and Eastern Europe, some regions in the 
Middle East), children escape infection in early childhood. 
Paradoxically, these improved economic and sanitary conditions 
may lead to a higher disease incidence, as infections occur in older 
age groups, and reported rates of clinically evident hepatitis A are 
higher.  
In developed countries (Northern and Western Europe, Japan, 
Australia, New Zealand, USA, Canada) with good sanitary and 
hygienic conditions, infection rates are generally low. In countries 
with very low HAV infection rates, disease may occur among specific 
risk groups such as travelers.  
 
Table 1: Worldwide Endemicity of Hepatitis A Infection 
 
HAV endemicity  REGIONS BY EPIDEMIOLOGICAL 
PATTERN  
AVERAGE AGE OF 
PATIENTS (YEARS)  
MOST LIKELY MODE OF 
TRANSMISSION  
Very high  AFRICA, PARTS OF SOUTH AMERICA, THE 
MIDDLE EAST AND OF SOUTH-EAST ASIA  
UNDER 5  PERSON-TO-PERSON, 
CONTAMINATED FOOD AND WATER  
High  BRAZIL'S AMAZON BASIN, CHINA AND 
LATIN AMERICA  
14-MAY PERSON-TO-PERSON,  OUTBREAKS/ 
CONTAMINATED FOOD OR WATER  
Intermediate  SOUTHERN AND EASTERN EUROPE, SOME 
REGIONS OF THE MIDDLE EAST  
24-MAY PERSON-TO-PERSON, OUTBREAKS/ 
CONTAMINATED FOOD OR WATER  
Low  AUSTRALIA, USA, WESTERN EUROPE  MAY-40 COMMON SOURCE, OUTBREAKS  
Very low  NORTHERN EUROPE AND JAPAN  OVER 20  EXPOSURE DURING TRAVEL TO HIGH 
ENDEMICITY AREAS, UNCOMMON 
SOURCE  
Source: (VHPB, 1997; Barzaga, 2000; Cianciara, 2000; Tanaka, 2000; Tufenkeji, 2000) 
Table 2: Estimated Number of Cases of Hepatitis A per Continental Region 
REGION  1990POPULATION (IN MILLIONS)  INCIDENCE (PER100,000 
PER YEAR)  
      CASES         
(PERYEAR 
North America   275  10  28,000  
CentralandSouthAmerica  453  20-40  162,000  
Europe  791  5-60   278,000  
Africa and Middle East  827  20-60  251,000  
Asia  2893  10-30  676,000  
Oceania  28  15-30  5,000  
Total        1,399,000  
Source: Hadler(1991) 
Modes of Transmission 
HAV is transmitted from person-to-person via the faecal-oral route 
(Hollinger and Ticehurst, 1996; Lemon, 1997). As HAV is abundantly 
excreted in faeces, and can survive in the environment for prolonged 
periods of time. Thus, hepatitis A may be acquired from faecally 
contaminated food or water and from waste water-contaminated 
drills or water supplies (Lemon, 1994; Hollinger and Ticehurst, 
1996). Direct person-to-person spread is common under poor 
hygienic conditions (Lemon, 1994). Occasionally, HAV is also 
acquired through sexual contact (anal-oral) and blood transfusions 
(Lemon, 1994). It is not transmitted from infected mothers to 
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newborn infants, as anti-HAV IgG antibodies present during initial 
tages of HAV infection across the placenta and provide protection to 
the infant after delivery. 
Incubation Period 
Once a person is exposed to the virus, it takes between 15 and 40 
days to produce symptoms (BMA, 2002). 
Signs and Symptoms 
It is possible to experience mild or no symptoms whatsoever, but 
even if this is the case, the person’s faeces will still be infectious to 
others (Ryder and Beckingham, 2001). However, signs and 
symptoms of HAV include a shot, mild, flu-like illness, nausea, 
vomiting and diarrhea, loss of appetite, weight loss, jaundice (yellow 
skin and white of the eyes, darker yellow urine and pale faeces), 
Itchy skin and abdominal pain. 
The infection usually clears in up to 2 months, but may occasionally 
reoccur or persists longer in some people. 
Risk Groups for Hepatitis A 
Certain groups can be defined as high risk for contracting HAV 
(Steffen, 1995; Hollinger and Ticehurst, 1996; Lemon, 1997; VHPB, 
1997; Koff, 1998). They include people in household/sexual contact 
with infected persons, medical and paramedical personnel in 
hospitals, international travelers from developed countries to 
regions of the world where HAV is endemic (3/1000 to 20/1000 
people per month's stay abroad), persons living in regions with 
endemic hepatitis A, persons residing in areas where extended 
community outbreaks exist, preschool children attending day-care 
centres, their parents and siblings, day-care centre employees, 
residents and staff of closed communities (institutions), refugees 
residing in temporary camps following catastrophes, homosexually 
active men, injecting drug users using unsterilized injection needles, 
persons with clotting factor disorders, persons with chronic liver 
disease, food-service establishments/food handlers and persons 
working with non-human primates  
Persons falling into any of the above mentioned categories should 
consider being vaccinated as a preventive measure. Risk factors 
remain unidentified in as much as 50% of hepatitis A cases (VHPB, 
1997; Koff, 1998). Hepatitis A is contracted at least 100 times more 
frequently than typhoid fever or cholera.  
Hepatitis B 
Hepatitis B is a serious and common infectious disease of the liver 
affecting millions of people throughout the world (Robinson, 1995; 
Chisari and Ferrari, 1997; Mahoney and Kane, 1999; Ganem and 
Schneider, 2001; Hollinger and Liang, 2001). Hepatitis B has also 
been called type B hepatitis, serum hepatitis, homologous serum 
jaundice (Robinson, 1995; Mahoney and Kane, 1999). Hepatitis B is 
an infectious illness caused by hepatitis B virus (HBV) which infects 
the liver of humans causing an inflammation which was originally 
known as serum hepatitis (Barker et al., 1996). The disease has 
caused epidemics in parts of Asia and Africa, and it is endemic in 
China (Williams, 2006). WHO (2009), reported that about a quarter 
of the world’s population (i.e. more than 2 billion people) have been 
infected with HBV and millions are chronic carriers of the virus 
(Ferriara, 2000; Draton et al., 2004; Cheesbrough, 2006). Hepatitis B 
virus is the most virulent of the entire hepatitis viruses. It may lead 
to a condition called cirrhosis (permanent scaring of the liver) or 
liver cancer, both of which cause severe illness and even death. If a 
person lives with HBV infection for a number of years, it may 
develop to liver cancer, liver cirrhosis or chronic hepatitis. HBV is 
estimated to be 50 to 100 times more infectious than HIV (Barker et 
al., 1996). 
In 2004, an estimated 350 million individuals were infected 
worldwide. National and regional prevalence ranges from over 10% 
in Asia to under 0.5% in the United States and northern Europe. 
Routes of infection include vertical transmission (such as through 
childbirth), early life horizontal transmission (bites, lesions, and 
poor sanitary habits), and adult horizontal transmission (sexual 
contact, intravenous drug use) (Custer et al., 2004). The primary 
method of transmission reflects the prevalence of chronic HBV 
infection in a given area. In low prevalence areas such as the 
continental United States and Western Europe, injection drug abuse 
and unprotected sex are the primary methods, although other 
factors may also be important (Redd et al., 2007). In moderate 
prevalence areas, which include Eastern Europe, Russia, and Japan, 
where 2–7% of the population is chronically infected, the disease is 
predominantly spread among children. In high prevalence areas 
such as China and South East Asia, transmission during childbirth is 
most common, although in other areas of high endemicity such as 
Africa; transmission during childhood is also significant (Alter, 
2003). The prevalence of chronic HBV infection in areas of high 
endemicity is at least 8%. As at 2010, China had 120 million infected 
people, followed by India and Indonesia with 40 million and 12 
million people respectively (WHO, 2004). According to WHO, an 
estimated 600,000 people every year are ill as a result of related 
infection (HSRH, 2011). The rest of the world falls into the 
intermediate range of HBV prevalence, with 2 to 8% of a given 
population being HBV carriers.  
Table 3: Worldwide Prevalence of hepatitis B 






















































Source: Zukerman (1996) 
Modes of Transmission 
HBV is transmitted from person to person through blood or other 
body fluids. The most important mode of HBV transmission globally 
is perinatal (i.e. from the mother to her newborn baby), most 
commonly during delivery. If a pregnant woman is HBV carrier and 
is also HBeAg-positive, her newborn baby has 90% likelihood to be 
infected and become a carrier. Among these children, 25% will die 
later from chronic liver disease or liver cancer (Hollinger and Liang, 
2001). Another important mode of HBV transmission is from child to 
child during early life resulting from blood contact (Gitlin, 1997). All 
patients with acute hepatitis B are HBeAg positive, and therefore 
highly infectious and careless contact with their blood or body fluids 
can lead to HBV infection.  
However, there are several other ways HBV can be spread. These 
include through unprotected sex, sharing contaminated needles and 
other drug-injecting equipment, as well as by using none sterilized 
equipment for tattooing, acupuncture or body piercing and through 
blood transfusion. (Sleinsenger et al., 2006; Kid-Ljunggren et al., 
2006; WHO, 2009). Also, HBV is stable on environmental surfaces for 
at least 7 days, and indirect inoculation of HBV can occur via 
inanimate objects like toothbrushes, baby bottles, toys, razors, 
eating utensils, hospital equipment and other objects, by contact 
with mucous membranes or open skin breaks (Robinson, 1995).  
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It is note worthy also that, HBV cannot be spread by casual contact 
such as holding hands, sharing eating utensils or drinking glasses, 
breast-feeding, kissing, hugging, coughing or sneezing (NIH, 2010). 
Incubation Period 
Once a person is exposed to HBV, the first signs and symptoms occur 
between 1 to 6 weeks. 
Signs and Symptoms 
Acute infection with hepatitis B virus begins with general ill- health, 
loss of appetite, nausea, vomiting, body aches, mild fever, dark urine, 
and then progress to development of jaundice. The illness lasts for a 
few weeks and then gradually improves in most affected people. The 
infection may be entirely asymptomatic and may go unrecognized 
(Terrault, 2005). 
Chronic infection with HBV may be either asymptomatic or may be 
associated with a chronic inflammation of the liver, leading to 
cirrhosis over a period of several years. This dramatically increases 
the incidence of hepatocellular carcinoma (liver cancer). HBV has 
been linked to the development of membranous glomerulonephritis 
(Gan et al., 2005). 











The 42 nm, double-shelled particle, 
originally called the Dane particle that 
consists of a 7 nm thick outer shell and 
a 27 nm inner core. The core contains a 
small, circular, partially double-
stranded DNA molecule and an 
endogenous DNA polymerase. This is 











The complex of antigenic determinants 
found on the surface of HBV and of 
22 nm particles and tubular forms. It 
was formerly designated Australia 
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The antigenic determinant that is 
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Specific antibodies that are produced 
in response to their respective 
antigenic determinants. 
  
Source: Hollinger and Liang (2001) 
Risk Groups for Hepatitis B 
Frequent and routine exposure to blood or serum is the common 
denominator of healthcare occupational exposure. Surgeons, 
dentists, oral surgeons, pathologists, operating room and emergency 
room staff and clinical laboratory workers who handle blood are at 
the highest risk (Robinson, 1995). However, according to Hollinger 
and Liang (2001) and Robinson (1995), groups of people who are at 
risk of contracting HBV include infants born to infected mothers, 
young children in day-care or residential settings with other 
children in endemic areas, sexual/household contacts of infected 
persons, health care workers, people sharing unsterile medical or 
dental equipment, people providing or receiving acupuncture 
and/or tattooing with unsterile medical devices, sexually active 
heterosexuals and homosexuals. Similarly, patients and employees 
in haemodialysis centres (CDCP, 1998; VHPB, 1998),  injection drug 
users sharing unsterile needles (VHPB, 1998) and persons living in 
regions or travelling to regions with endemic hepatitis B (WHO, 
1999) are also at risk of contracting the Virus. 
Hepatitis C 
Hepatitis C like other types of hepatitis causes inflammation of the 
liver. It is caused by hepatitis C virus (HCV). Like hepatitis B, 
Hepatitis C can lead to cirrhosis and liver cancer though; it is not as 
common as other types of hepatitis. Hepatitis C is the most serious 
type of hepatitis (Rockstroh, 2011). It is now one of the most 
common reasons for liver transplant in adults. It is transferred 
primarily through blood, and is more persistent than hepatitis A or B 
(Pollack, 2011).  
Mode of Transmission 
Hepatitis C can be transmitted from person to person by sharing 
drug-injecting equipment (needles, heating spoons etc), by using 
non-sterilized equipment for tattooing, acupuncture or body 
piercing, as well as by sharing equipment used to snort cocaine, 
because it can be contaminated with blood from a person’s nose. It 
can also be transmitted through exposure to blood during 
unprotected sex and through blood transfusion. 
It is rarely transmitted from an infected mother to her baby during 
child birth. However, the risk may be greater if the mother is also 
infected with HIV. Similarly, hepatitis C cannot be passed on by 
hugging, sneezing, coughing, sharing food or water, sharing cutlery 
or casual contact (NIH, 2010).  
Incubation Period 
A person who is infected with HCV begins to have first signs and 
symptoms between 6 to 12 months. 
Signs and Symptoms 
People with hepatitis C often get symptoms similar to those caused 
by other viral infections. Occasionally, a person will not develop any 
symptom and their immune system will successfully clear the virus 
without their knowledge, but can still act as a carrier and pass the 
virus on to others. However, symptoms may include a short, mild, 
flu-like illness, nausea and vomiting, diarrhea, loss of appetite, 
weight loss, jaundice, itching skin etc. 
Chronic infection with HCV may cause mild or no symptoms at all 
and may develop some complications such as liver cirrhosis and 
liver cancer if the person lives with it for a number of years. 
Causes of Hepatitis 
A group of viruses known as hepatitis viruses cause most cases of 
hepatitis worldwide. However, there are other factors that can cause 
hepatitis. These include alcohol consumption, utilization of some 
drugs, industrial organic solvents and plants, metabolic disorder, 
obstructive, autoimmune disease and ischemic hepatitis. 
Alcoholic Induced Hepatitis 
This is a hepatitis caused by alcohol. Ethanol mostly in alcoholic 
beverages is a significant cause of hepatitis (Parveen et al., 2005). 
Usually, alcoholic hepatitis results after a period of increased alcohol 
consumption. Hepatitis caused by alcohol is characterized by 
variable symptoms, which may include feeling unwell, enlargement 
of the liver, development of fluid in the abdomen ascites and modest 
elevation of liver enzymes. Long term alcohol consumption leads to 
development of hepatitis C. The combination of HCV and alcohol 
consumption accelerates the development of cirrhosis. 
Drug Induced Hepatitis 
A large number of drugs can cause hepatitis (Health A to Z, 2006). 
Such drugs include antidepressant (Agomelatine, Amitriptyline), 
antiarrythmic (Amiodarone), anesthetic gas (Halothane), 
Nonsteroidal anti-inflammatory drugs (NSAIDS)(Ibuprofen and 
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Indomethacin), antifungal (Ketoconazole), antihistamine 
(Loratadine), immune suppressant (Methotrexate), antihypertensive 
(Methyldopa), tetracycline antibiotics (Minocycline), 
antihypertensive (Nifidipine), antiepileptic (Phenytoine and Valproic 
acid), antiretroviral (Zidovudine), Hormonal contraceptives, 
Alloprinol, antibacterial (Isoniazid), acetaminophen (Paracetamol) 
and  antidiabetic (Troglitazone), but troglitazone was withdrawn in 
the year 2000 for causing hepatitis. It is note worthy that 
Paracetamol can only cause hepatitis when taken in an overdose 
 According to Nadir et al. (2000) and Bastida et al. (2005), 
Atomoxetine and Azathioprine respectively can cause hepatitis. 
However, the clinical cause of drug induced hepatitis is quiet 
variable; it depends on the drug and the patient’s tendency to react 
to the drug. For example, hormonal contraception can cause 
structural changes in the liver (Health A to Z, 2006), halothane 
induced hepatitis can range from mild to fatal as can INH-induced 
hepatitis, while Amiodarone induced hepatitis can be untreatable 
since it has a long half life of up to 60 days, which means that there is 
no effective way to stop exposure to the drug (Health A to Z, 2006). 
Statins can cause elevations of liver function blood tests normally 
without indicating an underlying hepatitis. However, human 
variability is such that any drug can be a cause of hepatitis.  
Industrial Organic Solvents and Plants induced Hepatitis 
Some other toxins can cause hepatitis. Examples are as follows: 
 Amatoxin-containing mushroom, including the death cap 
(Amanita phalloides, the destroying angel (Amanita acreata) 
and some species of Galerina (Parveen et al., 2005). It is 
noteworthy that a portion of single mushroom can be enough 
to be lethal 
 White phosphorous (an industrial toxins and war chemical) 
 Carbon tetrachloride, chloroform, trichloroethylene and all 
chlorinated hydrocarbon, cause steatohepatitis (hepatitis with 
fatty liver) 
 Cylindrospermopsin, a toxin from the cyanobacterium 
(Cylindrospermopsis raciborskii) and other cyanobacteria. 
Metabolic Disorder Induced Hepatitis 
This is a group of disorder in which some aspect of body chemistry is 
disturbed (BMA, 2002). Some metabolic disorders result from an 
inherited malfunction or deficiency of an enzyme. Others result from 
under or overproduction of a hormone that controls metabolic 
activity, such as occurs in diabetes mellitus and hypothyroidism. 
Also, Hemochromatosis (due to iron accumulation) and Wilson’s 
disease (copper accumulation) can cause liver inflammation and 
cirrhosis. All these and other metabolic disorders cause different 
forms of hepatitis. 
Autoimmune Disorder Induced Hepatitis 
Bacteria, Viruses and drugs may play a role in initiating an 
autoimmune disorder, but in most cases the trigger is unknown. 
Anomalous presentation of human leukocyte antigen (HLA) class II 
on the surface of hepatocyte possibly due to genetic predisposition 
or acute liver infection; causes a cell-mediated immune response 
against the body’s own liver, resulting in autoimmune hepatitis 
(BMA, 2002). Initial treatment for any autoimmune disorder is to 
reduce the effects of the disease by replacing hormones that are not 
being produced (BMA, 2002). But, in most cases in which the disease 
is having widespread effect, treatment is also directed at diminishing 
the activity of the immune system while maintaining the body’s 
ability to fight disease. Corticosteroid drugs are most commonly 
used but may be combined with other immunosuppressant drugs 
Ischemic Hepatitis 
Ischemia is the insufficient supply of blood to a specific organ or 
tissue (BMA, 2002). Ischemic hepatitis is therefore caused by 
decreased circulation to the liver cells (hepatocytes). Usually this is 
due to decreased blood pressure (or shock), leading to the 
equivalent term "shock liver". This is usually result from disease of 
the blood vessels such as atherosclerosis but, may also result from 
injury, constriction of vessel due to spasm of the muscles in the 
vessel wall, or inadequate blood flow due to insufficient pumping of 
heart. Patients with ischemic hepatitis are usually very ill due to the 
underlying cause of shock. Rarely, ischemic hepatitis can be caused 
by local problems with the blood vessels that supply oxygen to the 
liver (such as thrombosis, or clotting of the hepatic artery which 
partially supplies blood to liver cells and sickle cell crisis) (Raurich 
et al., 2009). Blood testing of a person with ischemic hepatitis will 
show very high levels of transaminase enzymes (AST and ALT), 
which may exceed 1000 U/L (Raurich et al., 2009). The elevation in 
these blood tests is usually transient (lasting 7 to 10 days). It is rare 
that liver function will be affected by ischemic hepatitis.  
People who develop ischemic hepatitis may have pain in the right 
upper part of the abdomen, but they usually feel more unwell 
because of the serious reason that they developed the ischemia, than 
due to the ischemic hepatitis itself (Raurich et al., 2009). Ischemic 
hepatitis is related to another condition called congestive 
hepatopathy or nutmeg liver, which is a backflow condition due to 
poor drainage of the liver, usually due to heart failure. As a result, 
the two entities can co-exist. Treatment may include vasodilator 
drug to widen the blood vessels or in more seven cases, an 
angioplasty or bypass operation (BMA, 2002). 
Effects of Hepatitis on Liver Cells 
The hepatitis virus mainly enters into the liver cell. The hepatitis cell 
latches onto the protein membrane and eases its way into the liver 
cell. Once inside the cell, this virus gene is free to take over the 
normal function of the liver cell. This causes the liver cell to become 
weak and then it dies. Before it dies the virus cell has used the liver 
cell to reproduce itself thousands of times. These new and multi 
virus cells now live and begin to take over all of the healthy liver 
cells. The whole process can take place in a matter of hours. This 
process must occur many times before a person begins to show signs 
of liver damage. It is when chronic hepatitis C or B goes untreated 
that it causes scarring to the liver (cirrhosis) and an increased 
chance of liver cancer, and liver failure ending in death. When 
hepatitis B or C virus enters the liver, it begins to invade the cells 
and grow. As it does this, the number of cells that are scarred and 
damaged increased. The person may not even feel any symptoms 
until so much damage has occurred, that their liver is unable to 
function any longer. This can take 10 to 40 years. This depends on 
the individual, genetics, and how well you take care of your liver. 
This however, may results to the following disease conditions: 
 Liver cirrhosis 
 Liver cancer 
 Jaundice and  
 Variations in Liver Panels  
 
Liver cirrhosis 
                                                            
 
Figure 2:  A) Normal liver                                                             B) 
Cirrohtic liver 
Cirrhosis is the end result after necrosis of the hepatocytes, with 
destruction of the normal lobular structure by fibrous septa and 
regenerative nodules of hepatocytes.  The clinical picture includes 
liver failure and signs of portal hypertension such as oesophageal 
varicose veins and ascites. The terminal stage is hepatic coma. 
Cirrhosis is scarring of the liver. It causes the formation of scar 
tissue on the liver because of injury or long-term disease. The most 
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common causes are chronic alcoholism and hepatitis. Other causes 
include disorder of bile duct, haemochromatosis, wilson’s disease, 
cystic fibrosis and heart failure (BMA, 2002). Two pathological types 
of liver cirrhosis are considered, they include Micronodular cirrhosis 
which is characterized by nodules less than 3 mm in diameter. This 
disorder was previously termed Laennec’s cirrhosis (after a French 
pathologist). The cause is alcohol abuse (alcoholic cirrhosis) or 
biliary tract disease (biliary cirrhosis) and Macronodular cirrhosis 
characterized by larger nodules sometimes including normal 
lobules. The cause is acute and chronic hepatic infection (hepatitis B 
virus, hepatitis C virus, hepatitis D virus) often in carriers. 
In cirrhosis, liver cells die and are progressively replaced with 
fibrotic tissue leading to nodule formation. The internal structure of 
the liver is deranged leading to the obstruction of blood flow and 
decrease in liver function. This damage is caused by recurrent 
immune responses stimulated by the presence of the virus. Cirrhosis 
can lead to Easy bruising or bleeding, or nosebleeds, swelling of the 
abdomen or legs, extra sensitivity to medicines, high blood pressure 
in the vein entering the liver, enlarged veins in the esophagus and 
stomach and kidney failure. Cirrhosis may go unrecognized until 
symptoms such as mild jaundice, oedema, and vomiting of blood 
develop. There may be enlargement of the liver and spleen and, in 
men, enlargement of the breasts and loss of body hair due to an 
imbalance in sex hormones caused by liver failure. Complications 
include ascites, oesophageal varies and hepatoma. Treatment is 
focused on slowing the rate at which liver cells are being damaged, 
by treating the cause for instance, hepatitis. In some cases, if the 




Fig. 3:  A) Hepatocellular Carcinoma in Cirrhotic and normal 
liver.  B) Histological appearance 
This is a cancerous tumour in the liver. The tumour may be primary 
(originating within the liver) or Secondary (having spread from 
elsewhere, often stomach, pancrease or large intenstine) (BMA, 
2002). There are two main types of primary tumour: a hepatoma, 
which develop in the liver cells, and a cholangiocarcinoma, which 
arises from cells lining the bile ducts. Seemingly healthy carriers of 
HBV and HCV are at risk of developing hepatocellular carcinoma.  
The -foetoprotein is raised in the blood plasma. Other risk factors 
for hepatocellular carcinoma are alcoholic damage, 
haemochromatosis, aflatoxin from peanuts, androgens, and 
oestrogens. A number of HBV patients with chronic hepatitis will 
develop hepatocellular carcinoma (Robinson, 1995; Hollinger and 
Liang, 2001). Persons at increased risk of developing HCC, are those 
who contracted hepatitis B in early childhood (Mahoney and Kane, 
1999). Only about 5% of patients with cirrhosis develop HCC. On the 
other hand, between 60 and 90% of HCC patients have underlying 
cirrhosis (Robinson, 1994; Robinson, 1995; Hollinger and Liang, 
2001). 
The incidence of HCC varies with geography, race, age, and sex. HCC 
is responsible for 90% of the primary malignant tumours of the liver 
observed in adults. Worldwide, it is the seventh most frequent 
cancer in males and ninth most common in females. Liver cancer is 
the cause of more than 500, 000 deaths annually throughout the 
world, with a male to female ratio of 4:1. The frequency of HCC 
follows the same general geographic distribution pattern as that of 
persistent HBV infection. The age distribution of patients with 
clinically recognized tumours suggests that these tumours appear 
after a mean duration of about 35 years of HBV infection (Robinson, 
1995; Hollinger and Liang, 2001). Patients who develop HCC as a 
result of malignant transformation of hepatocytes have a mean of 5-
year survival rate of 25 to 60% (Hollinger and Liang, 2001). This 
variation depends on the symptoms, the size of the tumour, its 
resectability, and the presence or absence of α-fetoprotein (AFP). 
Non-resectable tumours have a mean survival rate of 5 months for 
AFP-positive tumours and of 10.5 months for AFP-negative tumours 
(Hollinger and Liang, 2001). When serum α-fetoprotein (AFP) 
followed serially in HBsAg carriers rises significantly above the 
patient’s own baseline (>100 μg/ml), HCC can often be detected by 
liver scanning or ultrasound procedures at a stage when the tumour 
can be cured by surgical resection (Robinson, 1995). The diagnosis 
may be confirmed by liver biopsy. This suggests that HBsAg carriers 
should have regular serial serum AFP determinations and 
ultrasound examinations (at 6 months intervals for those above 40 
years). Both these tests are recommended to be repeated regularly 
for all HBsAg carriers with cirrhosis (Robinson, 1995). 
HBV causes 60-80% of the world’s primary liver cancer, and primary 
liver cancer is one of the three most common causes of cancer 
deaths in males in East and South-east Asia, the Pacific Basin, and 
sub-Saharan Africa (Robinson, 1995). Primary liver cancer is the 
eighth most common cancer in the world (Robinson, 1995). Up to 
80% of liver cancers are due to HBV. When HCC presents clinically, 
the disease is fatal. The median survival frequency of HCC patients is 
less than 3 months. However, if the cancer is detected early, there is 
85% chance of a cure. Treatment involves surgery, hepatic 
irradiation, and anticancer drugs. 
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A) Jaundice of the skin caused by hepatic failure B) A 4-year-
old boy with icteric (jaundiced) sclera  
Jaundice (also known as icterus; attributive adjective: icteric) is a 
yellowish pigmentation of the skin, the conjunctival membranes 
over the sclerae (whites of the eyes), and other mucous membranes 
caused by hyperbilirubinemia (increased levels of bilirubin in the 
blood) (Beckingham and Ryder, 2001). This hyperbilirubinemia 
subsequently causes increased levels of bilirubin in the extracellular 
fluid. Typically, the concentration of bilirubin in plasma must exceed 
1.5 mg/dl (Guyton et al., 2005). (>26µmol/L), three times the usual 
value of approximately 0.5 mg/dl for the coloration to be easily 
visible (Guyton et al., 2005). Jaundice comes from the French word 
jaune, meaning yellow. Jaundice is often seen in liver disease such as 
hepatitis or liver cancer. It may also indicate obstruction of the 
biliary tract, for example by gallstones or pancreatic cancer, or less 
commonly is congenital in origin.  
Hepatocellular (hepatic) jaundice is one the disease condition 
resulting from liver damage. It can be caused by acute hepatitis, 
hepatotoxicity, and alcoholic liver disease. Cell necrosis reduces the 
liver's ability to metabolize and excrete bilirubin leading to a 
buildup of unconjugated bilirubin in the blood. Other causes include 
primary biliary cirrhosis leading to an increase in plasma conjugated 
bilirubin because there is impairment of the liver for excretion of 
conjugated bilirubin into the bile. The blood contains abnormally 
raised amount of conjugated bilirubin and bile salts which are 
excreted in the urine. Jaundice seen in the newborn, known as 
neonatal jaundice, is common, occurring in almost every newborn as 
hepatic machinery for the conjugation and excretion of bilirubin 
does not fully mature until approximately two weeks of age 
(Pashankar and Schreiber, 2001). This form of jaundice is usually 
harmless and disappears within a week (BMA, 2002). Rarely, severe 
or persistent neonatal jaundice is caused by hepatitis or other 
infection. Neonatal jaundice may be treated with phototherapy but, 
in severe cases, Exchange transfusion may be needed. In hepatic 
jaundice, there is invariably cholestasis. Jaundice can also be seen in 
pregnancy women, and if left untreated may lead to the birth of 
babies with low intelligent quotient (IQ). 
Laboratory findings depend on the cause of jaundice. 
 Urine: Conjugated bilirubin present, urobilirubin > 2 units but 
variable (except in children). Kernicterus is a condition not 
associated with increased conjugated bilirubin.  
 Plasma protein show characteristic changes.  
 Plasma albumin level is low but plasma globulins are raised 
due to an increased formation of antibodies.  
Variations in Liver Panels 
Hepatitis and some other liver related diseases cause serious 
variations in the liver panels. These variations may either be below 
or above normal levels. Most patients presenting with jaundice 
which causes increased bilirubin as a result of hepatitis will have 
various predictable patterns of liver panel abnormalities, though 
significant variation does exist (Beckingham and Ryder, 2001). The 
typical liver panel will include blood levels of enzymes found 
primarily from the liver, such as the aminotransferases (ALT, AST), 
and alkaline phosphatase (ALP); bilirubin (which causes the 
jaundice); and protein levels, specifically, total protein and albumin. 
Other primary lab tests for liver function include GGT and 
prothrombin time (PT). 
ALP and GGT levels will typically rise with one pattern while AST 
and ALT rise in a separate pattern. If the ALP (10–45 IU/L) and GGT 
(18–85) levels rise proportionately about as high as the AST (12–38 
IU/L) and ALT (10–45 IU/L) levels, this indicates a cholestatic 
problem (Beckingham and Ryder, 2001). On the other hand, if the 
AST and ALT rise is significantly higher than the ALP and GGT rise, 
this indicates a hepatic problem. Alcoholic liver damage may see 
fairly normal ALT levels, with AST 10x higher than ALT. On the other 
hand, if ALT is higher than AST, this is indicative of hepatitis. Levels 
of ALT and AST are not well correlated to the extent of liver damage. 
Low levels of albumin tend to indicate a chronic condition, while it is 
normal in hepatitis and cholestasis. 
Lab results for liver panels are frequently compared by the 
magnitude of their differences, not the pure number, as well as by 
their ratios. The AST to ALT ratio can be a good indicator of whether 
the disorder is alcoholic liver damage (10), some other form of liver 
damage (above 1), or hepatitis (less than 1) (Guyton et al., 2005). 
Bilirubin levels greater than 10x normal could indicate neoplastic or 
intrahepatic cholestasis. Levels lower than this tends to indicate 
hepatocellular causes. AST levels greater than 15x tends to indicate 
acute hepatocellular damage. Less than this tend to indicate 
obstructive causes. ALP levels greater than 5x normal tend to 
indicate obstruction, while levels greater than 10x normal can 
indicate drug (toxic) induced cholestatic hepatitis or 
Cytomegalovirus (Beckingham and Ryder, 2001). Both of these 
conditions can also have ALT and AST greater than 20× normal. GGT 
levels greater than 10x normal typically indicate cholestasis. Levels 
5–10× tend to indicate viral hepatitis. Levels less than 5× normal 
tend to indicate drug toxicity. Acute hepatitis will typically have ALT 
and AST levels rising 20–30× normal (above 1000), and may remain 
significantly elevated for several weeks (Chernecky and Berger, 
2008). Acetaminophen toxicity can result in ALT and AST levels 
greater than 50x normal. 
DIAGNOSIS, TREATMENT AND PREVENTION OF HEPATITIS 
In this chapter, various ways through which hepatitis viruses could 
be diagnosed, treated and prevented are discussed. 
Diagnosis of Hepatitis 
The following are different ways through which various types of 
hepatitis can be diagnosed. They are as follows: 
Diagnosis of Hepatitis A 
Since both clinically and biochemically, acute hepatitis due to HAV 
cannot be distinguished from that due to the other hepatitis viruses, 
serologic tests are necessary for a virus-specific diagnosis (Hollinger 
and Ticehurst, 1996; Koff, 1998). Diagnosis of hepatitis is made by 
biochemical assessment of liver function (laboratory evaluation of 
urine bilirubin and urobilinogen, total and direct serum bilirubin, 
ALT and/or AST, alkaline phosphatase, prothrombin time, total 
protein, albumin, IgG, IgA, IgM, complete blood count). (Stepleton 
and Lemon, 1999; Hollinger and Ticehurst, 1996; Lemon, 1999; Koff, 
1998). However, the specific routine diagnosis of acute hepatitis A is 
made by finding anti-HAV IgM in the serum of patients. A second 
option is the detection of virus and/or antigen in the faeces (Lemon, 
1997; Koff, 1998).  
Similarly, Virus and antibody can be detected by commercially 
available RIA, EIA or ELISA kits. These commercially available assays 
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for anti-HAV IgM and total anti-HAV (IgM and IgG) for assessment of 
immunity to HAV are not influenced by the passive administration of 
IG, because the prophylactic doses are below detection level (Lemon, 
1997). At the onset of disease, the presence of IgG anti-HAV is 
always accompanied by the presence of IgM anti-HAV. As IgG anti-
HAV persists lifelong after acute infection, detection of IgG anti-HAV 
alone indicates past infection (Stepleton and Lemon, 1994; Hollinger 
and Ticehurst, 1996; Koff, 1998). Virus may still be present in the 
absence of detectable HAV antigen, as demonstrated by the use of 
more sensitive methods (Hollinger and Ticehurst, 1996). If 
laboratory tests are not available, epidemiologic evidence can help 
in establishing a diagnosis. 
Diagnosis of Hepatitis B 
Diagnosis of hepatitis B is made by biochemical assessment of liver 
function. Initial laboratory evaluation should include: total and 
direct bilirubin, ALT, AST, alkaline phosphatase, prothrombin time, 
total protein, albumin, serum globulin, complete blood count, and 
coagulation studies (Robinson, 1995; Hollinger and Liang, 2001). It 
is confirmed by demonstration in sera of specific antigens and/or 
antibodies. Three clinical useful antigen-antibody systems have been 
identified for hepatitis B: 
a. hepatitis B surface antigen (HBsAg) and antibody (anti-HBs) 
b. antibody (anti-HBc IgM and anti-HBc IgG) and hepatitis B core 
antigen (HBcAg) 
c. hepatitis B e antigen (HBeAg) and antibody (anti-HBe) 
HCV can be diagnosed by carrying out blood tests that detect HCV 
antibodies in the blood. 
Treatment of Hepatitis  
Hepatitis has no specific treatment and specific cure. Most people 
fight it naturally, returning to full health within a couple of months 
Treatment of Hepatits A 
As no specific treatment exists for hepatitis A, prevention is the most 
effective approach against the disease (Stapleton and Lemon, 1994; 
Andre, 1995). Therapy should be supportive and aimed at 
maintaining adequate nutritional balance (1 g/kg protein, 30-35 
cal/kg). Alcoholic beverages should not be consumed during acute 
hepatitis because of the direct hepatotoxic effect of alcohol. 
Hospitalization is usually not required (Stapleton and Lemon, 1994; 
Hollinger and Ticehurst, 1996).  
Temporary auxiliary liver transplantation for sub acute liver failure 
may be a way to promote native liver regeneration (Stapleton and 
Lemon, 1994; Battegay et al., 1995; Hollinger and Ticehurst, 1996). 
Also, patients with HAV should have enough rest and should stay 
well hydrated by drinking lots of fluids. 
Treatment of Hepatitis B 
Treatment of chronic hepatitis B is aimed at eliminating infectivity to 
prevent transmission and spread of HBV, at halting the progression 
of liver disease and improving the clinical and histological picture, 
and at preventing HCC from developing, by losing markers of HBV 
replication in serum and liver like HBV DNA, HBeAg, and HBcAg. 
Normalization of ALT activity, resolution of hepatic inflammation 
and the improvement of patients’ symptoms usually accompany 
these virological changes (Mahoney and Kane, 1999; Hollinger and 
Liang, 2001). 
There are two main classes of treatment: 
 antivirals: aimed at suppressing or destroying HBV by interfering 
with viral replication (Mahoney and Kane, 1999)  
 immune modulators: aimed at helping the human immune system 
to mount a defense against the virus. 
Acute hepatitis B does not usually require treatment 
because most adults clear the infection spontaneously (Hoolinger 
and Lau, 2006). Currently, there are seven medications licensed for 
treatment of chronic hepatitis B infection in the United States 
(Prammoolsinsop, 2002). These include antiviral drugs, Lamivudine 
(Epivir), Adefovir (Hepsera), Tenofovir (Viread), Telbivudine 
(Tyzeka) and Enticavir (Baroclude) and the two immune system 
modulators; interferon alpha-za and PEGylated interferon alpha-za. 
The treatment reduces viral replication in the liver, thereby reducing 
the viral load. Infant born to mothers known to carry hepatitis B can 
be treated with antibodies to the HBV (HBIg). Hepatitis B can also be 
treated by controlling the level of production of host-derived DNA 
building protein (Ng et al., 2005). 
Currently, chronic hepatitis B is treated with interferons (Robinson, 
1995; Gitlin, 1997; Mahoney and Kane, 1999; Hollinger and Liang, 
2001). The only approved ones are interferon-α-2a and interferon-
α-2b. Interferons display a variety of properties that include 
antiviral, immunomodulatory, and antiproliferative effects. They 
enhance T-cell helper activity, cause maturation of B lymphocytes, 
inhibit T-cell suppressors, and enhance HLA type I expression. To be 
eligible for interferon therapy, patients should have infection 
documented for at least six months, elevated liver enzymes (AST and 
ALT) and an actively dividing virus in their blood (HBeAg, and/or 
HBV DNA positive tests). Patients with acute infection, end stage 
cirrhosis or other major medical problems should not be treated. 
Interferon-α produces a long-term, sustained remission of the 
disease in 35% of those with chronic hepatitis B, with normalization 
of liver enzymes and loss of the three markers for an active infection 
(HBeAg, HBV DNA, and HBsAg). Complete elimination of the virus is 
achieved in some carefully selected patients (Robinson, 1995; 
Tasspoulos, 1997; Mahoney and Kane, 1999; Hollinger and Liang, 
2001).  
Interferon therapy for patients with HBV-related cirrhosis decreases 
significantly the HCC rate, particularly in patients with a larger 
amount of serum HBV DNA. In patients with HBeAg-positive 
compensated cirrhosis, virological and biochemical remission 
following interferon therapy is associated with improved survival. In 
patients with chronic HBV infection, the clearance of HBeAg after 
treatment with interferon-α is associated with improved clinical 
outcomes (Niedarau, 1996; Ikeda, 1998; Mahoney and Kane, 1999; 
Fattovich, 1999; Hollinger and Liang, 2001). Interferon-α (Intron A 
(interferon-α-2b), Schering Plough, and Roferon, (interferon-α-2a) 
Roche Labs) is the primary treatment for chronic hepatitis B, The 
standard duration of therapy is considered after 16 weeks. Patients 
who exhibit a low level of viral replication at the end of the standard 
regimen benefit most from prolonged treatment (Tassapoulos, 1997; 
Janssen, 1999). Permanent loss of HBV DNA and HBeAg are 
considered a response to antiviral treatment, as this result is 
associated with an improvement in necro-inflammatory damage, 
and reduced infectivity. Interferon in high doses causes fever, 
fatigue, malaise, and suppression of white blood cell and platelet 
counts. These effects are reversible when the therapy is stopped 
(Robinson, 1995).  
A new treatment introduced recently for chronic hepatitis B in 
adults with evidence of HBV viral replication and active liver 
inflammation is EPIVIR®-HBV (lamivudine, Glaxo Wellcome). The 
recommended 100 mg oral dose once-daily in form of tablets is easy 
to take and generally well tolerated, although safety and 
effectiveness of treatment beyond 1 year have not been established 
(Gitlin, 1997; Nevans, 1997; Lai, 1998; Mahoney and Kane, 1999; 
Dienstay, 1999).  
Lamivudine is a 2', 3'-dideoxy cytosine analogue that has strong 
inhibitory effects on the HBV polymerase and therefore on HBV 
replication in vitro and in vivo. Lamivudine is well tolerated and 
suppresses HBV replication in HBsAg carriers, but the effect is 
reversible, if therapy is stopped (Lai, 1997; Nevens, 1997; Gitlin, 
1997; Mahoney and Kane, 1999; Dienstay, 1999). Combination 
therapy with interferon-α and lamivudine for patients who failed 
interferon-α monotherapy is under investigation. Adoptive transfer 
of immunity to hepatitis B has been a novel approach to terminating 
HBV infection in the carrier after bone marrow transplantation from 
a hepatitis B immune donor (Gitlin, 1997; Hollinger and Liang, 
2001).  
Several new agents (e.g. Ritonavir, Adefovir, Dipivoxil, Lobucavir, 
Famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, Theradigm-HBV, 
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Thymosin-alpha, Ganciclovir (Hadziyannis and Manesis, 1999)) are 
in development, and some encouraging data are available. 
Table 5: Potential Drug Therapy for Chronic hepatitis B   































  adoptive 
immune transfer 
  
Source: (Gitlin, 1997) 
Contraindications of Interferon Therapy for Chronic Hepatitis B  
Interferon therapy is contraindicated in a patient who have 
problems such as Hepatic decompensation (albumin <3.0 g/l, 
bilirubin >51.3 μ mol/l (30 mg/l), prolonged prothrombin time >3.0 
s), Portal hypertension (variceal bleed, ascites, encephalopathy), 
Hypersplenism (leukopenia (<2 x 109/l), thrombocytopenia (<7 x 
107/l)), Psychiatric depression (severe, suicide attempt), 
Autoimmune disease (polyarteritis nodosa, rheumatoid arthritis, 
thyroiditis), Major system impairment (cardiac failure, obstructive 
airways A 
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DTP- diphteria, tetanus and pertussis; HB -  hepatitis B; Hib - 
Haemophilus influenza type b. 
Source: (Mahoney and Kane, 1999) 
CONLUSION 
Liver is the largest organ in the body, contributing about 2 % of the 
total body weight, or about 1.5 kg in the average adult human 
(Guyton and hall, 2006) and plays a vital role in the body because it 
produces and processes a wide range of chemical substances (BMA, 
2002).  From this study, it could be deduced that hepatitis viruses 
cause major effects in the physiology of liver cells. Moreover, Guyton 
and Hall (2006), stated that under abnormal conditions, may be 
when someone gets hepatitis, the liver will no longer perform the 
above functions as supposed to be and can be affected to varying 
degrees and when this happens, some of the biochemical parameters 
in the liver (liver panels) such as bilirubin, ALT, AST, albumin, total 
proteins e.t.c, will vary either above or below normal levels 
(Robinson, 1995; Hollinger and Liang, 2001). The varying levels of 
the liver panels indicate that liver has been impaired; this may be as 
a result of liver cirrhosis, liver cancer, jaundice etc. 
However, Sirisen (2000), classify Nigeria among the countries highly 
endemic for viral hepatitis. The major findings showed that hepatitis 
B virus (HBV) and hepatitis C virus (HCV) are the most dangerous 
form of hepatitis that destabilizes the welfare of man. Research 
showed that the prevalence of HBV was highest among Nigeria 
female Sex workers (FSWs) and among pregnant women who 
generally have depressed immunity. These findings corroborate 
reports of studies from Mexico which revealed that early age of 
sexual activity increases the risk of HBV infection (Vazquez-Martinez 
et al., 2003). This high prevalence among sex workers in Nigeria is 
indication that active sexual transmission is an important factor in 
the spread of HBV in this nation and that sex workers are a reservoir 
group for the maintenance and transmission of the virus. Research 
also revealed that chronic hepatitis is a leading cause of liver-related 
deaths among patients with HIV/AIDS worldwide (Koziel and Peters, 
2007). The risk groups who are more likely to be susceptible to both 
HAV and HBV infections are also revealed 
In conclusion, since the viruses are usually transmitted through 
sexual contact or from infected mother to the offspring especially at 
birth, there is the need for proper screening of all pregnant women 
and infants born to HBV positive mothers. Similarly, Persons falling 
into any of the above mentioned categories of risk groups should 
consider being vaccinated as a preventive measure. Moreover, 
Government and non-governmental Organizations (NGOs) should 
intensify efforts to enlighten the general public on the public health 
importance of the disease, and incorporate hepatitis screening into 
the routine antenatal check up. Also, UNICEF, WHO, and several 
other international donor agencies should help developing countries 
to obtain HB vaccine and implement national programmes on 
universal vaccination against hepatitis virus. We also call for 
innovative and immediate implementation of a general child and 
adolescent immunization against hepatitis, to prevent the further 
spread of these viruses. Since the prevalence of hepatitis is higher 
among the female sex workers (FSWs) in Nigeria because of their 
frequent sexual contact and many sexual partners, we therefore 
quickly call for innovative programmes incorporating wide spread 
HBV education and vaccination among sex workers in Nigeria, to 
achieve immediate benefit within the targeted high risk population 
as an immediate first step to the global fight against HBV infection.  
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